<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9701">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05692180</url>
  </required_header>
  <id_info>
    <org_study_id>D3250C00024</org_study_id>
    <nct_id>NCT05692180</nct_id>
  </id_info>
  <brief_title>A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)</brief_title>
  <acronym>DOMINICA</acronym>
  <official_title>Efficacy and Safety of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in&#xD;
      patients ≥ 6 to &lt; 18 years of age with severe eosinophilic asthma, including a&#xD;
      well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose&#xD;
      inhaled corticosteroid (ICS) plus at least one additional controller medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised, double-blind, parallel-group, placebo-controlled,&#xD;
      time-to-first-asthma-exacerbation event study designed.&#xD;
&#xD;
      There will be a screening period of 2 months to allow adequate time for the eligibility&#xD;
      criteria to be evaluated. The screening period may be reduced to not lesser than 4 weeks from&#xD;
      Visit 2a. Furthermore, the Screening Period may be extended up to 12 weeks (or longer, if&#xD;
      deemed necessary by the investigator), to accommodate treatment.&#xD;
&#xD;
      Visit 2 will be split into Part A (Visit 2a) and Part B (Visit 2b) to reassess eligibility&#xD;
      prior to randomisation and first dose of study treatment administration.&#xD;
&#xD;
      Patients will be randomised 1:1 to receive benralizumab or placebo.&#xD;
&#xD;
      The treatment period will consist of 2 parts: double-blind (DB) treatment period and&#xD;
      open-label extension (OLE) period.&#xD;
&#xD;
      The initial placebo-controlled, DB treatment period will be of variable duration. The minimum&#xD;
      duration of treatment in the DB treatment period for each patient will be 16 weeks. Patient&#xD;
      will continue in the DB treatment period until the patient experiences an exacerbation or the&#xD;
      required number of events have been observed in the study, whichever occurs sooner.&#xD;
&#xD;
      All patients who experience an asthma exacerbation in the DB treatment period may enter the&#xD;
      OLE period. The OLE period will be 48 weeks in the ≥ 12 to &lt; 18-year-old age group and 2&#xD;
      years (104 weeks) in the ≥6 to &lt; 12-year-old age group, where all patients will receive&#xD;
      benralizumab.&#xD;
&#xD;
      An end-of-the-treatment visit will occur 8 weeks after the last dose in the OLE.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2023</start_date>
  <completion_date type="Anticipated">September 18, 2029</completion_date>
  <primary_completion_date type="Anticipated">September 17, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first asthma exacerbation</measure>
    <time_frame>From Baseline (Week 0) to End of Treatment (EOT) in DB treatment period</time_frame>
    <description>The effect of benralizumab on asthma exacerbations in paediatric and adolescent patients with uncontrolled asthma will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline, during the DB treatment period in Interviewer-Administered Version of the Asthma Control Questionnaire (ACQ-IA)</measure>
    <time_frame>From Baseline (Week 0) to EOT in DB treatment period</time_frame>
    <description>The effect of benralizumab on asthma control and symptoms will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline, during the DB treatment period in Asthma symptom score</measure>
    <time_frame>From Baseline (Week 0) to EOT in DB treatment period</time_frame>
    <description>The effect of benralizumab on asthma control and symptoms will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline, during the DB treatment period in rescue medication use</measure>
    <time_frame>From Baseline (Week 0) to EOT in DB treatment period</time_frame>
    <description>The effect of benralizumab on asthma control and symptoms will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline, during the DB treatment period in night-time awakenings due to asthma</measure>
    <time_frame>From Baseline (Week 0) to EOT in DB treatment period</time_frame>
    <description>The effect of benralizumab on asthma control and symptoms will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline, during the DB treatment period in peak expiratory flow (PEF)</measure>
    <time_frame>From Baseline (Week 0) to EOT in DB treatment period</time_frame>
    <description>The effect of benralizumab on asthma control and symptoms will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum benralizumab trough concentration</measure>
    <time_frame>During Day -7, Day 56, Day 112, every 16 weeks and at EOT DB treatment period</time_frame>
    <description>The pharmacokinetics of benralizumab will be characterised.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-benralizumab antibodies</measure>
    <time_frame>During Day -7, Day 56, Day 112, every 16 weeks and at EOT DB treatment period</time_frame>
    <description>The immunogenicity of benralizumab will be characterised.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline, during the DB treatment period in Paediatric Asthma Quality of Life Questionnaire-Interviewer Administered (PAQLQ-IA) total score</measure>
    <time_frame>From Baseline (Week 0) to EOT in DB treatment period</time_frame>
    <description>The effect of benralizumab on asthma health-related quality of life will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline, during the DB treatment period, in spirometry, for pre-dose/pre-bronchodilator forced expiratory volume in one second (FEV1)</measure>
    <time_frame>From Baseline (Week 0) to EOT in DB treatment period</time_frame>
    <description>The effect of benralizumab on pulmonary function (FEV1) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline, during the DB treatment period, in spirometry, for post-bronchodilator FEV1</measure>
    <time_frame>From Baseline (Week 0) to EOT in DB treatment period</time_frame>
    <description>The effect of benralizumab on pulmonary function (FEV1) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Annualised asthma exacerbation rate (AAER) in the DB treatment period</measure>
    <time_frame>From Screening until the EOT double blind treatment period</time_frame>
    <description>The asthma exacerbations reported during the DB treatment period of the study will be described.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with Adverse events (AEs) and Serious adverse events (SAEs)</measure>
    <time_frame>From Screening period until EOT DB treatment period</time_frame>
    <description>The safety and tolerability of benralizumab will be evaluated.</description>
  </other_outcome>
  <other_outcome>
    <measure>The AAER in the OLE period</measure>
    <time_frame>From Week 0 until the EOT OLE period</time_frame>
    <description>The annualised rate of severe exacerbations in the OLE period will be assessed.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Benralizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Benralizumab as an active solution via a subcutaneous (SC) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a matching solution of the placebo via SC injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benralizumab</intervention_name>
    <description>Benralizumab active solution will be administered SC to the patients.</description>
    <arm_group_label>Benralizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution will be administered SC to the patients.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Capable of giving assent (signing the assent form) to participate in the study. The&#xD;
             caregiver of the patient must be capable of giving written informed consent for the&#xD;
             patient's participation in the study. Consent and assent forms must be completed prior&#xD;
             to any study specific procedures.&#xD;
&#xD;
          -  Patient and the caregiver (where applicable) must be willing to and be able to answer&#xD;
             questionnaires that are part of the study procedures.&#xD;
&#xD;
          -  Male or female patients aged ≥ 6 to &lt; 18 years old.&#xD;
&#xD;
          -  Patients with a diagnosis of eosinophilic asthma, defined by regional for at least 12&#xD;
             months prior to Visit 1.&#xD;
&#xD;
          -  Patients with a diagnosis of severe asthma confirmed, evaluated, and managed by the&#xD;
             clinical site for ≥ 6 months prior to Visit 1.&#xD;
&#xD;
          -  Patients with an exacerbation history of asthma exacerbations (defined as a&#xD;
             requirement for systemic corticosteroids and/or hospitalization) within 12 months&#xD;
             prior to Visit 1, OR,&#xD;
&#xD;
               1. 2 asthma exacerbations (defined as a requirement for systemic corticosteroids&#xD;
                  and/or hospitalization) per year within the 2 years prior to Visit 1 AND, one or&#xD;
                  more of the following:&#xD;
&#xD;
               2. Currently on stable maintenance oral corticosteroids (OCS) used for at least 3&#xD;
                  months prior to Visit 1, OR,&#xD;
&#xD;
               3. At least one of the 2 exacerbations that occurred in the year prior to Visit 1&#xD;
                  resulted in hospitalisation.&#xD;
&#xD;
          -  Patients on well-documented, stable treatment for asthma with high dose ICS and at&#xD;
             least 1 additional controller medication, such as long-acting β2 agonists (LABA),&#xD;
             leukotriene receptor antagonists (LTRA), long-acting muscarinic antagonists (LAMA), or&#xD;
             theophylline, since at least 6 months prior to Visit 1.&#xD;
&#xD;
          -  Eosinophilic airway inflammation that is related to asthma characterised as&#xD;
             eosinophilic in nature as indicated by peripheral blood eosinophil count of ≥ 300&#xD;
             cells/μL during screening OR a blood eosinophil count of 150 to 299 cells/μL and&#xD;
             documentation of elevated eosinophils in bronchoalveolar lavage (BAL), sputum, or&#xD;
             bronchial biopsy within the 2 years prior to Visit 1.&#xD;
&#xD;
          -  ≥ 70% compliance with maintenance asthma medication during the screening period based&#xD;
             on the Paediatric Asthma Symptom - Observer reported (PASO) or Asthma Daily Diary.&#xD;
&#xD;
          -  At least 70% daily PASO or Asthma Daily Diary completion during the entire screening&#xD;
             period, with at least 50% PASO or Asthma Daily Diary completion in the 14-day period&#xD;
             prior to randomisation.&#xD;
&#xD;
          -  Pre-BD FEV1 ≤ 95% PN or pre-BD FEV1/FVC ratio &lt; 0.85 required. Patients with ≥ 25 %&#xD;
             increase in mean pre-BD FEV1 value during the screening period will be screen failed.&#xD;
&#xD;
          -  ACQ-IA ≥ 1.5 with no meaningful improvement (ACQ-IA change ≤ -0.5) between screening&#xD;
             and Visit 2a.&#xD;
&#xD;
          -  Body weight ≥ 15 kg.&#xD;
&#xD;
          -  Females of childbearing potential (FOCBP) who are sexually active, as judged by the&#xD;
             investigator, must commit to consistent and correct use of a highly effective and&#xD;
             acceptable method of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically important pulmonary disease other than asthma or patients who have ever&#xD;
             been diagnosed with pulmonary or systemic disease, other than asthma, that are&#xD;
             associated with elevated peripheral eosinophil counts&#xD;
&#xD;
          -  Life-threatening asthma,&#xD;
&#xD;
          -  Asthma exacerbation requiring use of systemic corticosteroids or increase in&#xD;
             maintenance dose of OCS within 2 weeks prior to Visit 2a or acute upper/lower&#xD;
             respiratory infection that requires antibiotics or antiviral medication within 2 weeks&#xD;
             prior to the first dose of the IP (Visit 2b).&#xD;
&#xD;
          -  Any disorder that is not stable in the opinion of the investigator and could affect&#xD;
             the safety of the patient during the study, influence the findings of the studies or&#xD;
             their interpretations or impede the patient's ability to complete the entire duration&#xD;
             of the study.&#xD;
&#xD;
          -  History of anaphylaxis to any biologic therapy.&#xD;
&#xD;
          -  Current malignancy, or history of malignancy.&#xD;
&#xD;
          -  A helminth parasitic infection&#xD;
&#xD;
          -  Use of immunosuppressive medication&#xD;
&#xD;
          -  Receipt of immunoglobulin or blood products within 30 days prior to Visit 1.&#xD;
&#xD;
          -  Receipt of any marketed or investigational biologic within 4 months or 5 half-lives&#xD;
             prior to Visit 1&#xD;
&#xD;
          -  Previously received benralizumab (MEDI-563).&#xD;
&#xD;
          -  Participation in another interventional clinical study&#xD;
&#xD;
          -  Patients with known hypersensitivity to benralizumab or any of the excipients of the&#xD;
             product.&#xD;
&#xD;
          -  Currently pregnant, breastfeeding, or lactating females.&#xD;
&#xD;
          -  Previous randomisation in the present study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33184</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>08724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northfield</city>
        <state>New Jersey</state>
        <zip>08225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B7600FYW</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1414AIF</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad de Buenos Aire</city>
        <zip>C1425DTG</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florencio Varela</city>
        <zip>1888</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florida</city>
        <zip>B1602DQD</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lobos</city>
        <zip>7240</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500GIP</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000ASF</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7L 6W6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 1G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon</city>
        <zip>69394</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nice cedex 1</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <zip>77019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <zip>41469</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wesel</city>
        <zip>46483</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genova</city>
        <zip>16100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ponte San Pietro</city>
        <zip>24036</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheongju-si</city>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jung-gu</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-624</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skarżysko-Kamienna</city>
        <zip>26-110</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cartagena</city>
        <zip>30203</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <zip>8950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mérida</city>
        <zip>06800</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE2 7LZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>E1 4NS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>January 11, 2023</study_first_submitted>
  <study_first_submitted_qc>January 11, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2023</study_first_posted>
  <last_update_submitted>May 16, 2023</last_update_submitted>
  <last_update_submitted_qc>May 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eosinophilic asthma</keyword>
  <keyword>Pediatric Patients</keyword>
  <keyword>Severe asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Pulmonary Eosinophilia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benralizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.&#xD;
All requests will be evaluated as per the AZ disclosure commitment:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

